Our chief executive officer Brent Barnes updates Proactive Investors on developments to forge ahead with product sales of its unique APAS Independence technology.

The ground-breaking medical technology company has also raised $5 million on the back of FDA clearance, which will enable the execution of commercialisation plans.

Barnes will attend this week’s American Society of Microbiology Microbe meeting in San Francisco to further showcase the APAS Independence to the US and global markets